News

Cognition Therapeutics CEO Excited for Upcoming Conferences

Cognition Therapeutics CEO Excited for Upcoming Conferences

Cognition Therapeutics Leadership at Healthcare Conferences

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a pioneering biopharmaceutical company dedicated to developing therapies for neurodegenerative disorders, is excited to announce that its CEO, Lisa Ricciardi, will participate in significant healthcare conferences soon. These events are pivotal for the company as they coincide with the annual JP Morgan Healthcare Conference.

Progress in Alzheimer’s and Neurodegenerative Research

In her recent statements, Ms. Ricciardi expressed enthusiasm about discussing the remarkable strides made during the previous year concerning their Alzheimer's and Dementia with Lewy Body (DLB) programs. Notably, 2024 was a defining year for Cognition Therapeutics as they marked the successful completion of their Phase 2 SHIMMER study, yielding promising topline results for DLB patients. This achievement propels them towards presenting their findings at the upcoming International Lewy Body Dementia Conference, set to be held in late January.

Upcoming Presentations

Beyond the conference presentations, Cognition's leadership is also preparing for a pivotal end-of-Phase 2 meeting with the FDA to review results from their SHINE study, which focuses on mild to moderate Alzheimer's disease. This meeting represents a critical milestone for regulatory and development strategies. Furthermore, the company has received clearance for the generic name of its neurodegenerative drug candidate, which will now be known as zervimesine.

Details of Conference Participation

Here are some crucial details regarding the conferences where Ms. Ricciardi will present:

Longwood Healthcare Leaders Stanford Summit

Date: January 11, 2025
Panel: Accelerating Drug Development
Location: The Four Seasons, San Francisco, CA

Sachs 8th Annual Neuroscience Innovation Forum

Date: January 12, 2025
Panel: Innovation in AD/PD & Other Cognitive Disorders
Corporate Presentation: 1:40 PM Track C Heritage Room
Location: Marines' Memorial Club, San Francisco, CA

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. specializes in discovering and developing groundbreaking small molecule therapeutics aimed at age-related neurodegenerative disorders affecting the central nervous system and retina. Currently, they are focused on their lead candidate, zervimesine (formerly known as CT1812), which is being investigated in clinical trials for Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration (dry AMD). The company believes that their unique approach utilizing ?-2 receptor modulators offers new strategies to regulate the disrupted pathways associated with these conditions.

Vision for the Future

Cognition Therapeutics aims to continue its innovative trajectory by advancing its clinical programs that could significantly impact the treatment landscape for neurodegenerative diseases. The company is committed to improving patient outcomes through dedicated research and development efforts.

Frequently Asked Questions

What is Cognition Therapeutics working on?

The company focuses on developing treatments for Alzheimer's disease, dementia with Lewy bodies, and other related cognitive disorders.

What is the significance of zervimesine?

Zervimesine is Cognition's lead candidate, targeting pathways impaired in neurodegenerative conditions. It was previously known as CT1812.

When will Cognition Therapeutics present their findings?

They are set to present at the International Lewy Body Dementia Conference later this month and participate in various panels at upcoming healthcare conferences.

Who is the CEO of Cognition Therapeutics?

Lisa Ricciardi is the CEO, and she will be representing the company at major health conferences this January.

What are the upcoming events Cognition Therapeutics is attending?

The company will participate in the Longwood Healthcare Leaders Stanford Summit and the Sachs 8th Annual Neuroscience Innovation Forum.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BIBIBOP Brings Good Vibes with OLIPOP Happy Hour

Updated Category News Views 131

Boosting Midday Energy with BIBIBOP's New Promo Here we go, folks. BIBIBOP Asian Grill is dialing up the culinary energy just when you need it most. From November 16 to 22, during their Good Energy Happy Hour, they’re serving up a deal designed to pump some pep into your afternoon—free OLIPOP prebiotic soda with any regular bowl purchase. Just stroll into any of their...

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 97

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Koppers Faces SEC Scrutiny After Earnings Miss

Updated Category News Views 169

Koppers' Third-Quarter Blues: Missing the Mark Koppers Holdings Inc. (NYSE: KOP) took a hard hit this quarter, missing Wall Street's earnings expectations by a mile. The adjusted earnings per share came in at just $0.77, while the suits down on Wall Street were expecting something closer to $1.34 to $1.37. Now, if you’re holding KOP in your portfolio, you're probably...

Continue Reading
Cardinal Infrastructure Faces Legal Scrutiny Amid Losses

Updated Category News Views 125

Cardinal Infrastructure Group Under Intense Investor Scrutiny Well, ain't this a messy soup of financial blunders? Cardinal Infrastructure Group (Nasdaq: CDNL) finds itself on the sharp end of a potential securities law investigation, thanks to some colossal screw-ups in managing project costs and estimates. Investors are rightly pissed after the company's shares...

Continue Reading
Biointron's RushDATA™: Speeding Up Antibody Discovery

Updated Category News Views 227

A New Chapter in Antibody Discovery Well, color me intrigued. Biointron, a name you'd recognize if you've got even a toe in the biotech pond, just threw a serious curveball into the antibody discovery game with RushDATA™—an AI- and machine learning-driven platform that's packing a punch. And it's not just about throwing tech buzzwords around; this thing clocks...

Continue Reading
Will Hair Loss Drugs Challenge Transplant Clinics?

Updated Category News Views 73

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 137

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 108

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 219

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
Purdue's xGTT: Pioneering a New Trust Standard in Tech

Updated Category News Views 150

A Bold New Benchmark in Tech Trust You've got to hand it to the folks at Purdue's Krach Institute—they're not dancing around the fringes but diving straight into the thick of it with their Global Trusted Tech Standard, or xGTT. This isn't just another checkbox for compliance nerds. The xGTT is all about building trust in technology that's woven with democratic values...

Continue Reading

Top 5 Most Recently Viewed Articles

HawkEye 360 Expands Capabilities with Strategic NRO Partnership

Updated Category News Views 189

HawkEye 360's New Partnership with the NRO HawkEye 360, recognized as a leader in sharing signals intelligence data and analytics, has recently secured a significant funding extension from the National Reconnaissance Office (NRO) alongside the Commercial Systems Program Office (CSPO). This collaborative effort is set to span over 23 months, aiming to enhance the...

Continue Reading
Consumer Sentiment and Its Impact on Economic Reflation Trends

Updated Category News Views 88

Understanding Consumer Sentiment Trends In recent discussions, we have explored how indicators like inflation gauges can influence economic forecasts. A notable aspect is consumer sentiment, which provides insights into spending behaviors and overall market confidence. Recent readings suggest a surprising optimism among consumers, especially in light of complex inflation...

Continue Reading
Ocular Therapeutix Announces Major Stock Offering Ahead of Trials

Updated Category News Views 264

Ocular Therapeutix's Strategic Stock Offering Announcement Ocular Therapeutix, Inc. (Nasdaq: OCUL), known for its commitment to enhancing retinal health, has declared an exciting new chapter in its journey. The company has recently confirmed the pricing for an underwritten public offering of 37,909,018 shares of its common stock, set at $12.53 per share. This significant...

Continue Reading
Roku Ads Manager: Innovations for Today’s Marketing Landscape

Updated Category News Views 145

Roku Unveils Ads Manager for Growth-Driven Marketers Roku (NASDAQ: ROKU) has stepped up its game in the streaming industry by launching a new platform named Roku Ads Manager. This self-service tool is tailored specifically for marketers eager to improve their connected television (CTV) campaigns. The rollout of this innovative platform comes as advertising trends shift...

Continue Reading
Evaxion Secures $10.8 Million in Strategic Public Offering

Updated Category News Views 97

Evaxion Biotech's Recent Public Offering Evaxion Biotech A/S (NASDAQ: EVAX) has recently made headlines with its announcement of a public offering. The company, renowned for its pioneering work in AI-Immunology™, has set the offering's combined public price at $2.71 per ADS, with warrants allowing the purchase of equal representation. This promising move emphasizes...

Continue Reading